chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient has not reported any side effects.; child received an adult Covid vaccine for their primary series; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (child received an adult Covid vaccine for their primary series) and NO ADVERSE EVENT (Patient has not reported any side effects.) in a 10-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044C22A) for COVID-19 prophylaxis.     Previously administered products included for Vaccination: Hepatitis A. Past adverse reactions to the above products included No adverse event with Hepatitis A.    On 03-Jan-2023, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Jan-2023,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (child received an adult Covid vaccine for their primary series). On 03-Feb-2023, the patient experienced NO ADVERSE EVENT (Patient has not reported any side effects.). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (child received an adult Covid vaccine for their primary series) and NO ADVERSE EVENT (Patient has not reported any side effects.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (Patient has not reported any side effects.) to be not related. No further causality assessment was provided for PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (child received an adult Covid vaccine for their primary series).    No Concomitant medication was reported. It was reported by HCP that on 03Jan2023 a child received an adult Covid vaccine for their primary series. Patient has not reported any side effects. This was the patients second dose. No treatment information was provided.
It is reported that a pt rec'd Menomune A/C/Y/W-135, unknown lot #, on 9/18/02. He had a vasovagal reaction and was placed in a supine position. Vitals were taken; blood pressure of 118/60, pulse 84, and respiration's 20 per minute. Ammonia was administered and the pt came around immediately. Pt recovered.
Sore arm at injection site; Sore arm at injection site; This is a spontaneous report from a contactable consumer (patient). A 63-year-old female patient received the first dose of BNT162B2 (Pfizer-BIONTECH Covid-19 Vaccine; Lot number: EL1284), via an unspecified route of administration in the left arm on 13Jan2021 at 18:30 as a single dose for COVID-19 immunization. Medical history included Sjogren's Syndrome, connective tissue disorder, high blood pressure, was pre-diabetic, and had a known allergy to penicillin. The patient had other medications in two weeks (unspecified). The patient was not pregnant, had no other vaccines in four weeks, and did not have COVID prior to the vaccination. The patient experienced sore arm at injection site on 13Jan2021 at 21:00. The patient did not receive any treatment for the events. She was not COVID tested post-vaccination. Outcome of the event was recovered.
Petechiae on cheeks and posterior forearms started about 3 days after having 1/16/22 COVID vaccine. Treated with Vanicream, hydrocortisone and triamcinolone with no improviement.
MMR given 6-30-15. Low grade temp 7-8-15. Rash pinpoint -> pea sized 7-10-15.
No Fever, developed diarrhea and vomiting late evening.  Brother had diarrhea the early morning of 11/10/2009.
Pt presented with second occurrence of tenderness to palpitation, induration, edema, pain and redness distally to elbow. Patient was diagnosed with localized cellulitis to vaccination site by staff.  Patient treated with Motrin 800mg 1 tab PO Q8hrs PRN, Allegra 60mg 1 tab PO TID, and Septra DS 800mg/60mg 1 tab PO BID.
After 1st and 2nd dose, arm was completely un-movable from pain and soreness.  After 2nd dose extremely tired. After 2nd dose both legs were tingly and weak and had shooting pains from thighs to kneecaps the next day, this continued all day.
Patient received covid vaccine at 1606. At 1616, pt reported feeling lightheaded and tingly. Was assisted to supine position, BP 128/79, HR 62. Was monitored by administering and RRT nurse. At 1630, pt reported symptoms completely resolved. Pt discharged at baseline status.
My lungs and my heart became full of pain and very swollen and lasted 2 days and nights. It felt worse when I sat up, coughed, raised my voice and walked up and down stairs. My heart felt like a filled up tight balloon and it hurt a lot. I looked it u and I think they describe this as mycarditus.
injection site warm; injection site hard; injection site itchy; injection site swollen; big red welt; This spontaneous case was reported by a patient and describes the occurrence of INJECTION SITE WARMTH (injection site warm), VACCINATION SITE INDURATION (injection site hard), VACCINATION SITE PRURITUS (injection site itchy), VACCINATION SITE SWELLING (injection site swollen) and VACCINATION SITE ERYTHEMA (big red welt) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included ETHINYLESTRADIOL, ETONOGESTREL (NUVARING), METFORMIN, LISINOPRIL, GLIPIZIDE, SPIRONOLACTONE, DOXYCYCLINE and vitamin c.    On 12-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 13-Jan-2021, the patient experienced INJECTION SITE WARMTH (injection site warm), VACCINATION SITE INDURATION (injection site hard), VACCINATION SITE PRURITUS (injection site itchy), VACCINATION SITE SWELLING (injection site swollen) and VACCINATION SITE ERYTHEMA (big red welt). At the time of the report, INJECTION SITE WARMTH (injection site warm), VACCINATION SITE INDURATION (injection site hard) and VACCINATION SITE PRURITUS (injection site itchy) outcome was unknown and VACCINATION SITE SWELLING (injection site swollen) and VACCINATION SITE ERYTHEMA (big red welt) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medication was reported.
Patient presented to clinic with a single dose Moderna on their card, requesting a second dose. A dose was given, which was later discovered to be a third dose
given half dose booster for pfizer .  remedied today with full dose per cdc guidelines with the above error.
The patient is a  51 yo old  reservist with a history of hypercholesterolemia with an onset  of illness 10 days after Pfizer vaccine (lot #2 ELI283) on 6 JAN 2021, where he was on 87 day active duty orders with Medical Task Force - COVID mission. He denies any AE after dose #1 (Dec  17 lot #ELD140). He denies any immediate symptoms suggesting IgE event(pruritis, urticaria, SOB, wheezing, oral, facial throat, tongue swelling etc.)  and denies any local site reaction. He reports about 10 days later he experienced severe nausea vomiting and diarrhea, CP and SOB. He was seen in ER 3 times where he was found to have Acute Kidney injury, and treated with IVF, odansetron meclizine dicyclimine. After the third ER visit he was admitted where he subsequently developed GI pain. He has continued to have significant health issues, but no unifying diagnosis has been identified.  He would like to know if this was related to his Covid vaccine receipt. He reports no one else in his group will ill and they were otherwise isolated for travel related Covid quarantine. Per review of records he presented to ER  17 JAN 2021 (day 11) with complaints of nausea global weakness, watery diarrhea, and shortness of breath . He had a acute kidney injury with cr 1.4. A non contrast ABD CT was normal. He was diagnosed with viral gastroenteritis, treated with hydration, Zofran and Bentyl. He returned to ER 19 JAN (day 13) with a complaint of same with severe dizziness. A noncontrast head CT was normal He had a positive Dix-Hallpike and he was diagnosed with benign positional vertigo. On 1/20/21 (day 23) he continued symptoms with tachypnea on minimal exertion noted in ER. CXR demonstrated lateral RLL opacity and he was treated with Rocephin and azithromycin. He developed vague abdominal pain and was transferred to MTF. 26 JAN 21  GASTROENTEROLOGY: EGD - 'marked chronic active gastritis' - blood, stool sample and gastric biopsies are negative for H pylori infection - Protonix 40mg BID CT of kidney showed cyst on the left and nonobstructive 3mm stone and creatinine on is 0.9 (0.7-1.2).
Breakthrough case admission after 2 vaccines  Moderna 6/8/21 lot# 025B21A;  Moderna 7/7/21 lot# 040B21A
Fever, chills, headache, dizziness, weakness, sweating, shaking.
On 9/9/22 in the evening I got chills,low grade fever,sweats,fatigue. Woke up at 7am 9/10 feeling general malaise in a pool of sweat, went back to bed until 10:30am.  Stood at the sink to brush my teeth felt I was losing consciousness,tried to lower myself to the floor but passed out was on floor don?t know how long but when conscious again called for help  injured my head and coccyx
the patient got a positve COVID-19 test result; the patient got a positve COVID-19 test result; This is a spontaneous report from a contactable other healthcare professional (hcp). This hcp reported the same events for 2 patients. This is the second of two reports.   A patient of unspecified age and gender received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number and expiration date were unknown), via an unspecified route of administration on an unspecified date at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient got a positve COVID-19 test result on 05Jan2021. Outcome of the events was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product BNT162B2 to the reported drug ineffective and COVID-19 cannot be ruled out.,Linked Report(s) : US-PFIZER INC-2021020999 same drug/events/reporter, different patients
Shoulder pain causing significant discomfort and limited range of motion (now 12 days later)
1. Sore arm at vaccine entry.    2. Sore lump below the armpit/ not sure if it's the lymph node-  continuing 3 days later.
Event occurred after 2nd dose.  Patient is an 86-year-old male with a history of degenerative joint disease who presents to the ED for loss of appetite. He has also been weak and not wanting to get out of bed  Vitamin C, Zinc  Discharged
Patient had covid vaccine and then 1 day later, developed worsening PVCs. Patient has a history of PVCs and Vtach for which he has a pacemaker. Patient is historically very symptomatic with his PVCs. These worsened over the course of a week which lead to worsening substernal chest pain and he presented to the ER on 3/15/2021 and due to his history of CAD, was hospitalized for observation, discharged on 3/16/2021. He had labs, echocardiogram while in the hospital. His metoprolol was increased to help decrease symptomatic PVCs. On 3/9/2021, patient developed chills, difficulty swallowing and the sensation of his throat and tongue being swollen, along with some generalized itching. He presented to the ER 3/9/2021 due to these symptoms and these symptoms resolved without interventions and he was discharged home. He then developed lower lip swelling on 3/15/2021.
I developed a red rash over most of my left hand on the top from my thumb to my ring finger almost to my pinky. The rash hurt, peeled, stinging sensation with oozing fluid. I was diagnosed with eczema and prescribed a topical cream triamcinolone, then betamethasone dipropionate, and it still has not resolved. I had never had a skin issue ever before the vaccine, and this appeared a couple of days after dose 3 of Moderna COVID 19 Vaccine.
Patient experienced vasovagal syncope 2 to 3 minutes post vaccine. He passed out for about 20 seconds and his dad states he was convulsing. He was assisted to the clinic where he was provided 2 glucose tablets and had his vitals checked. Vitals were within normal limits. Throughout the next 30 minutes, patient continued to display cognitive awareness and finished about 12 oz of water. He was able to stand up on his own without feeling light headed. About 40 minutes post vaccine, he left to eat dinner. The family intends to see a physician prior to his second dose.
This case meets vaccine breakthrough criteria .  PATIENT ADMITTED AFTER BECOMING UNRESPONSIVE POST DIALYSIS
Red shingles rash on front of right leg from just below the knee all the way down to the ankle, about 18" long, and width varying from 3 inches down to 1/2 inch.
4 days after shot, nausea, fatigue, loss of strength, body aches, chills.
First dose felt like waking from anesthesia.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 54 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 12Mar2021 (Batch/Lot number: unknown) at the age of 54 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Latex Allergy" (unspecified if ongoing), notes: known allergies:  Latex. Eye drops; "Eye drops" (unspecified if ongoing), notes: known allergies:  Latex. Eye drops. Concomitant medication(s) included: VIT D [COLECALCIFEROL]. The following information was reported: ANAESTHESIA (non-serious) with onset 2021, outcome "unknown", described as "First dose felt like waking from anesthesia.". The event "first dose felt like waking from anesthesia." was evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of anaesthesia.  Patient was not received any other vaccines within 4 weeks prior to the COVID vaccine. Patient was not diagnosed with COVID-19 prior to vaccination nor been tested for COVID-19 since the vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
pt recv vax in 9/95 & in 6/98 pt exp rash, fever, swollen lymph node & headache.
Fever (T 106.9 F) an rash on trunk, four lesions in mouth occurring 8 days after vaccines around 10-20 lesions on body.
Received the first dose of hte Pfizer COVID19 vaccine on 4/8/2021. Developed cold-like symptoms on Friday, 4/9/2021, including: congestion, headache and right ear pain. On Saturday, 4/10/2021, had persistent headache, congestion and right ear pain. Also develoepd tingling on the right side of her face. She was evaluated at  Urgent Care on 4/10/2021 and recommended supportive care for right ear pain. On Sunday, 4/11/2021, developed complete paralysis of the right side of her face. She was evaluated in office on 4/12/2021 and diagnosed with Bell's Palsy based on exam - patient with complete right sided facial paralysis. She was treated with prendisone taper  (prendisone 60 mg for 7 days, then 40 mg for 3 dyas, then 20 mg for 3 days) and Valtrex 1000 mg three times daily for 1 week.
My daughter received pneumonia vaccine which resulted in petechiae several hours later. ER visit. After administration 1 yr later she was unable to bear weight on her leg. After consulting the pediatrician the next day she was diagnosed w/ synovitis, she was in severe pain, unable to move leg.
soreness; swelling; pain in neck; joint pain; muscle pain; itching; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (soreness), VACCINATION SITE SWELLING (swelling), NECK PAIN (pain in neck), ARTHRALGIA (joint pain) and MYALGIA (muscle pain) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical history information was reported.     On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced MYALGIA (soreness), VACCINATION SITE SWELLING (swelling), NECK PAIN (pain in neck), ARTHRALGIA (joint pain), MYALGIA (muscle pain) and PRURITUS (itching). The patient was treated with NAPROXEN SODIUM (ALEVE) at an unspecified dose and frequency. At the time of the report, MYALGIA (soreness), VACCINATION SITE SWELLING (swelling), NECK PAIN (pain in neck), ARTHRALGIA (joint pain), MYALGIA (muscle pain) and PRURITUS (itching) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 24-Feb-2021 and was forwarded to Moderna on 24-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (soreness), VACCINATION SITE SWELLING (swelling), NECK PAIN (pain in neck), ARTHRALGIA (joint pain) and MYALGIA (muscle pain) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical history information was reported.     On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced MYALGIA (soreness), VACCINATION SITE SWELLING (swelling), NECK PAIN (pain in neck), ARTHRALGIA (joint pain), MYALGIA (muscle pain) and PRURITUS (itching). The patient was treated with NAPROXEN SODIUM (ALEVE) at an unspecified dose and frequency. At the time of the report, MYALGIA (soreness), VACCINATION SITE SWELLING (swelling), NECK PAIN (pain in neck), ARTHRALGIA (joint pain), MYALGIA (muscle pain) and PRURITUS (itching) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.
Brain metastases. ED visit to hospital admission. This visit was within 6 weeks of receiving the COVID vaccine.
This spontaneous report as received from a Licensed Practical Nurse refers to a patient of 11 years old child patient and unknown gender. On 05-AUG-2014 the patient was vaccinated with a dose of an improperly stored GARDASIL (lot J009788, expiration date 17-MAR-2016)(dose, route, were not reported). No adverse effect was reported. The outcome of events reported was unknown. No product quality complaint was involved. This is one of several reports received from the same source. Additional information has been requested.
rxn w/in 5mins wheal dime sized w/2in erythema around it; tx w/ice pack
Pt. is a 4 year old male. Source of patient information was mother. Patient accompanied by mother. Feeling fine. Normal appetite. Skin symptoms; No fever. No head symptoms. No swollen glands in the neck. No eye symptoms. No ear symptoms, no nasal discharge, no nasal passage blockage, and no sore throat. No dyspnea, no cough, and no wheezing. No nausea, no vomiting, and no diarrhea. No oliguria. Received immunization 2 days ago and now right arm swollen red and hot to the touch. Received Hep A injection in right arm. Fluid intake is normal.
Patient received second dose of Moderna 2 weeks after first dose. 2 weeks before they should have. Sat for 30minutes while monitored  took vitals  HR 98, RR 22, O2 99% RA. Lungs clear on auscultation. Instructed to call pediatrician and make an appt which family did for next day. No adverse reaction.
vial was stored  greater than 12 hours post-puncture; 3 Moderna COVID-19 Booster Shots were given to patients greater than 12 hours post-puncture; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (3 Moderna COVID-19 Booster Shots were given to patients greater than 12 hours post-puncture) and PRODUCT STORAGE ERROR (vial was stored  greater than 12 hours post-puncture) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002M21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Apr-2022 at 1:44 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Apr-2022 at 1:44 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (3 Moderna COVID-19 Booster Shots were given to patients greater than 12 hours post-puncture). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (vial was stored  greater than 12 hours post-puncture). At the time of the report, EXPIRED PRODUCT ADMINISTERED (3 Moderna COVID-19 Booster Shots were given to patients greater than 12 hours post-puncture) and PRODUCT STORAGE ERROR (vial was stored  greater than 12 hours post-puncture) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications details were not reported by the reporter. Patient received first Booster dose. Number of doses/vials: 3 booster doses / 1 vial (15.5 ml) Red Cap Date the vial was initially stored in the refrigerator: 22 APRIL 2022 Date and time vial was first punctured: 22 APRIL 2022 at 9:55AM vial was stored in the Refrigerator post puncture. No temperature excursions Total amount of time the vial was exposed to room temperature range (8° to 25°C= 46° to 77°F): 22APR2022 for 2 hours; 25APR2022 1 hour and 26APR2022 1.5 hours at room temperature.  The rest of the time the vial was in the refrigerator Treatment details was not reported by the reporter.   This case was linked to MOD-2022-551984, MOD-2022-551989 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Apr-2022: Live Significant follow up-Added vaccine and event related information. On 28-Apr-2022: Live follow up-added secondary phone number of reporter
FLUVIRIN vaccine administered in Rt arm 9/16/09 @ 3:30pm and overnight developed swollen, red, hardened left side of neck.  Came back to pharmacy & advised to see MD.
ACUTE NON ST ELEVATION MI 3/7/2022 CEREBRAL INFARCTION THROMB BIL CAROTID ARTERIES
Metallic taste in mouth started approximately 1 hour after receiving vaccine and still reporting metallic taste. Tingling on tongue started after receiving vaccine and went away after a few days.
Swollen lips, swollen jaw, changes in eye sight, warm arm at injection site, fever, warmth in legs, weakness
This spontaneous report was received from a patient referring to himself a currently 55 year old male patient. The patient did not have pertinent medical history or concurrent condition and was not taking a concomitant medication. On approximately 11-OCT-2016 (referred as about "4 or 5 weeks ago"), the patient was vaccinated with ZOSTAVAX in the right upper arm (route, dosage schedule, lot # and expiration date were not reported) for prophylaxis. On approximately 25-OCT-2015 (reported as "2 weeks later"), the patient started experiencing pain with a burning sensation on torso. The patient sought for medical attention but did not received any treatment for the event. Laboratory test were not performed. The outcome for the patient's pain with burning sensation on torso was unknown at the reporting time. The reporter did not assess causality between the event and the use of ZOSTAVAX. There was not a product quality complaint (PQC) involved. Additional information has been requested.
11JUL96 mom noted hives in evening was given DPH;12JUL96 hives on stomach & back was given DPH;13JUL96 10AM hives gone-no breathing problems cont DPH;